

Jiang Ming

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9823774/publications.pdf>

Version: 2024-02-01

8
papers

118
citations

1478505
6
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

85
citing authors

#	ARTICLE	IF	CITATIONS
1	Design of a novel Pt(II) complex to reverse cisplatin-induced resistance in lung cancer via a multi-mechanism. Dalton Transactions, 2022, 51, 5257-5270.	3.3	4
2	Developing a Copper(II) Agent Based on His-146 and His-242 Residues of Human Serum Albumin Nanoparticles: Integration To Overcome Cisplatin Resistance and Inhibit the Metastasis of Non-small Cell Lung Cancer. Journal of Medicinal Chemistry, 2022, 65, 9447-9458.	6.4	18
3	Designing biotin-human serum albumin nanoparticles to enhance the targeting ability of binuclear ruthenium(III) compound. Journal of Inorganic Biochemistry, 2021, 215, 111318.	3.5	3
4	Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 6777-6791.	6.4	23
5	Developing a Novel Indium(III) Agent Based on Liposomes to Overcome Cisplatin-Induced Resistance in Breast Cancer by Multitargeting the Tumor Microenvironment Components. Journal of Medicinal Chemistry, 2021, 64, 14587-14602.	6.4	15
6	Synthesis of a series of novel In(III) 2,6-diacetylpyridine bis(thiosemicarbazide) complexes: structure, anticancer function and mechanism. Dalton Transactions, 2020, 49, 17207-17220.	3.3	10
7	Developing a Novel Gold(III) Agent to Treat Glioma Based on the Unique Properties of Apoferritin Nanoparticles: Inducing Lethal Autophagy and Apoptosis. Journal of Medicinal Chemistry, 2020, 63, 13695-13708.	6.4	30
8	Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor Microenvironment. Molecular Pharmaceutics, 2020, 17, 1405-1414.	4.6	15